Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2009.22.3214 on August 31 2009

Journal of Clinical Oncology, Vol 27, No 29 (October 10), 2009: pp. 4919-4926
© 2009 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Khorana, A. A.
Right arrow Articles by Lyman, G. H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khorana, A. A.
Right arrow Articles by Lyman, G. H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

REVIEW ARTICLES

Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action

Alok A. Khorana, Michael B. Streiff, Dominique Farge, Mario Mandala, Philippe Debourdeau, Francis Cajfinger, Michel Marty, Anna Falanga, Gary H. Lyman

From the James P. Wilmot Cancer Center, and the Department of Medicine, University of Rochester, Rochester, NY; Johns Hopkins Medical Institutions, Baltimore, MD; Service de Médecine Interne et Pathologie Vasculaire and L'Institut National de la Santé et de la Recherche Médicale Unit U 976; Department of Oncology, Hôpital Saint-Louis, Assistance Publique Hopitaux de Paris, Denis Diderot Paris 7 University; Department of Medical Oncology (Pr Khayat), Hôpital de la Salpêtrière, Assistance Publique Hôpitaux de Paris, University Paris VI, Paris; Department of Oncology and Internal Medicine, Hôpital des Armées de Desgenettes, Lyon, France; Division of Medical Oncology and the Thrombosis and Hemostasis Center, Department of Hematology-Oncology, Ospedali Riuniti, Bergamo, Italy; and Duke University and the Duke Comprehensive Cancer Center, Durham, NC.

Corresponding author: Alok A. Khorana, MD, 601 Elmwood Ave, Box 704, Rochester, NY 14642; e-mail: alok_khorana{at}URMC.rochester.edu.

Purpose Venous thromboembolism (VTE) is an increasingly frequent complication of cancer and its treatments, and is associated with worsened mortality and morbidity in patients with cancer.

Design The Italian Association of Medical Oncology, the National Comprehensive Cancer Network, the American Society of Clinical Oncology, the French National Federation of the League of Centers Against Cancer, and the European Society of Medical Oncology have recently published guidelines regarding VTE in patients with cancer. This review, authored by a working group of members from these panels, focuses on the methodology and areas of consensus and disagreement in the various clinical guidelines as well as directions for future research.

Results There is broad consensus regarding the importance of thromboprophylaxis in hospitalized patients with cancer, including prolonged prophylaxis in high-risk surgical patients. Prophylaxis is not currently recommended for ambulatory patients with cancer (with exceptions) or for central venous catheters. All of the panels agree that low molecular weight heparins are preferred for the long-term treatment of VTE in cancer. Areas that warrant further research include the benefit of prophylaxis in the ambulatory setting, the risk/benefit ratio of prophylaxis for hospitalized patients with cancer, an understanding of incidental VTE, and the impact of anticoagulation on survival.

Conclusion We call for a sustained research effort to investigate the clinical issues identified here to reduce the burden of VTE and its consequences in patients with cancer.

A.F. and G.H.L. are co-senior authors of this article.

Supported by Grant No. 5K23CA120587-03 from the National Cancer Institute, Grant No. 1R01HL095109-01the National Heart, Lung and Blood Institute, and the V Foundation (A.A.K.); Grant No. 29/07 Oncological Research from the Italian Ministry of Health (A.F.); and by Grant No. 1R01HL095109-01 from the National Heart, Lung and Blood Institute (G.H.L.).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
JCOHome page
G. H. Lyman and A. A. Khorana
Cancer, Clots and Consensus: New Understanding of an Old Problem
J. Clin. Oncol., October 10, 2009; 27(29): 4821 - 4826.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2009 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online